Agenus Inc (AGEN)

May 05, 2026

Agenus (AGEN) officer Garo Armen takes May 2026 salary in stock - Stock Titan

May 05, 2026

May 04, 2026

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update - Business Wire

May 04, 2026

May 04, 2026

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance

May 04, 2026

May 02, 2026

AGEN SEC FilingsAgenus 10-K, 10-Q, 8-K Forms - Stock Titan

May 02, 2026

May 01, 2026

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - TMX Newsfile

May 01, 2026

May 01, 2026

AGEN News | AGENUS INC (NASDAQ:AGEN) - ChartMill

May 01, 2026

Apr 30, 2026

[ARS] AGENUS INC SEC Filing - Stock Titan

Apr 30, 2026

Apr 30, 2026

Agenus (NASDAQ: AGEN) proxy outlines equity pool increase and option exchange - Stock Titan

Apr 30, 2026

Apr 29, 2026

AGENUS EV-to-OCF: -2.51 | Fairly Valued - GuruFocus

Apr 29, 2026

Apr 29, 2026

MSN Money - MSN

Apr 29, 2026

Apr 29, 2026

Agenus (NASDAQ:AGEN) Shares Cross Above 200 Day Moving AverageHere's Why - MarketBeat

Apr 29, 2026

Apr 28, 2026

Director Susan B. Hirsch receives 105,000 Agenus (NASDAQ: AGEN) stock options - Stock Titan

Apr 28, 2026

Apr 28, 2026

Equity grants: Agenus (AGEN) awards 305,000 stock options to director-officer Buell - Stock Titan

Apr 28, 2026

Apr 28, 2026

[Form 4] AGENUS INC Insider Trading Activity - Stock Titan

Apr 28, 2026

Apr 28, 2026

Director Timothy Wright receives 105K AGEN (NASDAQ: AGEN) stock options grant - Stock Titan

Apr 28, 2026

Apr 28, 2026

Agenus (NASDAQ: AGEN) accounting chief awarded stock options in lieu of cash bonus - Stock Titan

Apr 28, 2026

Apr 28, 2026

Stock options granted to Agenus (AGEN) director and officer Armen Garo - Stock Titan

Apr 28, 2026

Apr 28, 2026

Agenus (AGEN) director Brian Corvese granted 210,000 stock options - Stock Titan

Apr 28, 2026

Apr 28, 2026

Agenus (AGEN) price target increased by 48.39% to 23.46 - MSN

Apr 28, 2026

Apr 28, 2026

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace

Apr 28, 2026

Apr 27, 2026

Agenus to Host First 2026 Stakeholder Webcast - The National Law Review

Apr 27, 2026

Apr 23, 2026

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs - 투데이안

Apr 23, 2026

Apr 23, 2026

Here's Why Agenus (AGEN) is a Strong Momentum Stock - Yahoo Finance

Apr 23, 2026

Apr 23, 2026

Agenus Q4 2025 earnings preview - MSN

Apr 23, 2026

Apr 22, 2026

AGEN (Agenus Inc.) Q4 2025 loss far narrower than expected, shares rise 3.23 percent in today’s session.Community Trade Ideas - Xã Thanh Hà

Apr 22, 2026

Apr 22, 2026

Agenus presents four abstracts on cancer therapies at ASCO By Investing.com - Investing.com India

Apr 22, 2026

Apr 22, 2026

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 - BioSpace

Apr 22, 2026

Apr 21, 2026

Agenus designa a BAP Pharma como socio global exclusivo para BOT+BAL - The Joplin Globe

Apr 21, 2026

Apr 21, 2026

Agenus (NASDAQ: AGEN) director Armen receives 3,403 fully vested shares as salary - Stock Titan

Apr 21, 2026

Apr 21, 2026

Promising Phase I Results for BOT/BAL and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Oncodaily

Apr 21, 2026

Apr 21, 2026

Agenus presents four abstracts on cancer therapies at ASCO - Investing.com

Apr 21, 2026

Apr 21, 2026

Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 21, 2026

Apr 20, 2026

Agenus enters global partnership with BAP Pharma for investigational BOT+BAL access - Traders Union

Apr 20, 2026

Apr 20, 2026

Agenus (NASDAQ: AGEN) asks shareholders to approve 5M shares, highlights BOT+BAL data - Stock Titan

Apr 20, 2026

Apr 20, 2026

Agenus cancer cocktail records 0% response rate, missing midstage goal - BioSpace

Apr 20, 2026

Apr 20, 2026

Is Agenus (AGEN) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Apr 20, 2026

Apr 19, 2026

Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN

Apr 19, 2026

Apr 17, 2026

Agenus reports trial data for cancer drug combination therapy By Investing.com - Investing.com Australia

Apr 17, 2026

Apr 17, 2026

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Lelezard

Apr 17, 2026

Apr 17, 2026

Agenus (AGEN) Presents Promising Trial Results for Advanced Canc - GuruFocus

Apr 17, 2026

Apr 17, 2026

Agenus Reports Phase II Data Demonstrating Immune Reprogramming a - The National Law Review

Apr 17, 2026

Apr 17, 2026

Agenus reports trial data for cancer drug combination therapy - Investing.com

Apr 17, 2026

Apr 17, 2026

Agenus cancer drug combo kept 43% alive at 18 months in study - Stock Titan

Apr 17, 2026

Apr 17, 2026

Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Eastern Progress

Apr 17, 2026

Apr 17, 2026

Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Eastern Progress

Apr 17, 2026

Apr 16, 2026

April 2026 Overview Highlights BOT+BAL Progress in MSS Colorectal Cancer – Agenus - Oncodaily

Apr 16, 2026

Apr 15, 2026

Agenus unveils 2026 catalyst roadmap with focus on BOT plus BAL and BATTMAN expansion - Traders Union

Apr 15, 2026

Apr 15, 2026

Agenus : Corporate Overview - marketscreener.com

Apr 15, 2026